In March 2018, Chinese Premier Li Keqiang announced that China will reduce tariffs on imported cancer drugs to zero percent. The plan should give a boost to global drug makers such as AstraZeneca, Novartis, Pfizer, and Roche by making their treatments more... Read More
China’s Center for Drug Evaluation (CDE) completed 9,680 drug filings in 2017, slashing the backlog of filings to 4,000 from a high of 22,000 in September 2015. A total of 394 market approvals were issued during the year, made up of 278... Read More
China’s government plans to expand health insurance for catastrophic illnesses to cover more than 20 million people by the end of 2018, Premier Li Keqiang announced in March 2018. More than 17 million people were covered by the program at the end... Read More
This article was originally published on MedTech Intelligence. Last year, Research and Markets released a report projecting that China’s in vitro diagnostics (IVD) market is likely to triple in size before 2022. This growth is driven by an aging population, a growing... Read More
The China Food and Drug Administration (CFDA) is the administrative body responsible for the regulation of medical devices and pharmaceuticals on the Chinese mainland. The CFDA is separated into various departments that are individually responsible for the registration, tracking, and monitoring of medical... Read More
In March 2018, China’s National People’s Congress approved plans for the China Food and Drug Administration (CFDA) to be merged into a newly formed National Market Supervision Administration, part of an overhaul of ministries. A new State Drug Administration under the merged... Read More
On February 6, 2018, China’s Food and Drug Administration (CFDA) and the Center for Medical Device Evaluation (CMDE) issued a new draft guidance for the approval of medical devices intended to treat rare diseases. The guidelines set out requirements for applicants to... Read More
Up until now, China has only had a few Diagnosis-Related Groups (DRGs), and they have not been a factor in China’s healthcare scheme. However, in February 2018, China’s Ministry of Human Resources and Social Security (MoHRSS) released a list of 130 diseases... Read More
Until recently, almost all risky medical devices and in vitro diagnostics (IVDs) were required to conduct local clinical studies in China to be receive registration approval there. In 2017, the China Food and Drug Administration (CFDA) issued guidelines for the acceptance of... Read More
The rise of more advanced treatments and medical facilities in Asia is driving strong growth in the market for endoscopic devices, according to a report by Transparency Market Research. The use of endoscopic devices in the diagnosis of various diseases and infections... Read More